Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer
Status:
Withdrawn
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
Cabazitaxel is already approved by the Food and Drug Administration (FDA) for use in patients
with advanced prostrate cancer, following docetaxel therapy. The purpose of this study is to
better understand the response and toxicity of cabazitaxel of elderly men (age 75 years and
older) with advanced prostate cancer who have progressed during or after treatment with
docetaxel. All patients on this study will receive cabazitaxel by intravenous (through a
vein) infusion plus prednisone by mouth twice daily, and following the chemotherapy
infusions, an injection of a granulocyte colony-stimulating factor (G-CSF). G-CSF will help
the body produce more white blood cells, which should help decrease the risk of getting an
infection while being treated with cabazitaxel.